MREO

Mereo BioPharma Group plc ADR (MREO) | Rumor.io

Mereo BioPharma Group

MREO

Attention (50-day avg)0%

Attention rank (50-day avg)#1,133

Bullish sentiment (50-day avg)87%

Price to earnings ratio-1.48

Market capitalization59.1M

Earnings per share-0.2

Dividend yield (TTM)—

Revenue (annual)500K

Net income (annual)-41.9M

Social

What share of all stock conversation is about MREO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0% +0	0% 0	0% +0

Sep 23

Mereo BioPharma Group plc's stock price has broken new highs, reaching over $0.04.
Some investors are holding onto their shares, despite the stock's volatility, and are optimistic about its potential.
There is speculation that Syntln will confirm the execution of Avlestat's options, which could have a significant impact on Mereo BioPharma Group plc's future.

Generated by AI

Sentiment

Of the messages about MREO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	94.57% -0.83	90.42% +8.55	82.68% +4.1
Bearish	0% 0	5.43% +0.83	9.58% -8.55	17.32% -4.1

Bullish· Aug 11

The company's market capitalization is around $50M, and with the pro-form cash, the valuation seems reasonable, especially considering the deal is not yet closed.
The recent news has surprised some investors, and with the potential for another extension, it could be interesting to see if the stock makes an organic move up.
The chart is very bullish, and with a large volume of 32 mil premarket, the stock could test $1, and there's still room on the chart for a move overhead.

Bearish· Jan 20

The author suggests that the recent surge in MREO's price is due to manipulation rather than genuine momentum.
The stock's structure is broken, and it has shifted to a clear downtrend with lower highs and bearish momentum.
The author believes that MREO's price drop is due to a lack of fundamental value and is being driven by a scam or a fake biopharm stock.

Generated by AI

Topics

Of the messages about MREO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	90.63%	95.08%	66.14%
Technical Analysis	50%	6.25%	3.28%	5.1%
Earnings	0%	0%	0%	1.64%
Analysts	50%	3.13%	1.64%	13.28%
Controversies	0%	0%	0%	2.29%
Macro	0%	0%	0%	11.55%

Announcements· Aug 11

Mereo BioPharma Group plc has entered into an option and license agreement with Sentynl Therapeutics for the US rights to alvelestat, a potential first-in-class oral treatment for alpha-1 antitrypsin deficiency-associated lung disease, with Mereo eligible to receive $40M in upfront payments and up to $435M in milestones.
The agreement also includes double-digit tiered royalties on U.S. net sales of alvelestat, and Sentynl gains US commercial rights and worldwide manufacturing of alvelestat for AATD-associated lung disease.
Mereo BioPharma has announced its second-quarter 2026 results, with a narrowed net loss of $7.0 million, and has extended its cash runway into late 2027 as the Phase 3 partnership advances for alvelestat in AATD-LD.

Technical Analysis· Jun 17

$MREO will steady climb all day, with pull backs after new highs bringing intraday RSI back to oversold quickly.
A trend line for $MREO is expected to hold, with bulls in control as long as it does, and a potential breakout to 1.60-1.70 if it retests highs.
$MREO has positive volume and a head and shoulders pattern, with a potential next leg taking it to 1.60-1.70, and a re-test of 1.58 before breaking through.

Generated by AI

Community

Of the messages about MREO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	53.66%	57.14%	59.18%	44.09%
Newcomers	46.34%	42.86%	40.82%	55.91%

Regulars· Aug 11

Mereo BioPharma and Sentynl Therapeutics have entered into an option and license agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, with Mereo eligible to receive $40M in upfront payments and up to $435M in milestones.
The agreement is expected to advance the Phase 3 study design for alvelestat, with the companies collaborating to refine the global study design and advance manufacturing.
Mereo's stock price has surged following the announcement, with some analysts predicting the company may be acquired by Zydus Lifesciences Ltd, and others anticipating potential milestone payments of up to $669M.

Newcomers· Sep 23

The newcomers are focused on the potential for a significant increase in the price of Mereo BioPharma Group plc, with some users expressing excitement about the possibility of the stock "popping" overnight.
The users are discussing various price levels and targets, including adding shares when the price reaches $1.75 and selling for $2 or more.
There is speculation about upcoming catalysts and the possibility of investors averaging up, with one user suggesting that the stock may be moving due to news from Syntln about the execution of Avlestat's options.

Generated by AI

News

Cantor Fitzgerald reiterates Mereo BioPharma stock Overweight rating at $3

11d agoInvesting.com

Analysts Conflicted on These Healthcare Names: Veeva Systems (VEEV), Mereo Biopharma Group Plc (MREO) and Tvardi Therapeutics (TVRD)

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

13d agoThe Globe and Mail

Mereo BioPharma receives extension from Nasdaq to regain minimum bid price compliance

1mo agoInvesting.com

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mereo BioPharma will be eligible for $40m in upfront and research and development payments, and up to $435m in milestones.

1mo agoYahoo Finance

Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances

The rare-disease biotech cut its quarterly net loss while a new Sentynl agreement could provide $40 million in upfront and R&D payments and funding for alvelestat’s planned Phase 3 study. Key Investor TakeawaysMereo BioPharma (NASDAQ:MREO) extended its cash runway guidance into late 2027, ending June with $30.

1mo agoYahoo Finance

Mereo BioPharma licenses alvelestat to Sentynl Therapeutics

1mo agoInvesting.com

Also Discussed

Investors talking about MREO also mention

#	Name	Attention
1	Ultragenyx Pharmaceutical Inc.RARE	0.01%+0.01
2	PDS Biotechnology CorporationPDSB	0%-0.01
3	Pavmed Inc.PAVM	0%0
4	EFTR - eFFECTOR Therapeutics, Inc.	——
5	ONCT - Oncternal Therapeutics, Inc.	——
6	ACHL - Achilles Therapeutics plc	——
7	Lucid Diagnostics Inc.LUCD	0%+0
8	MDxHealth SAMDXH	0%0
9	Autolus Therapeutics plc ADRAUTL	0%+0
10	DAWN - Day One Biopharmaceuticals, Inc.	——

Mereo BioPharma Group plc ADR

Healthcare
Biotechnology

Mereo BioPharma Group plc ADR is a biopharmaceutical company focused on developing and commercializing therapeutics for rare diseases and oncology. The company’s current portfolio includes product candidates such as setrusumab for osteogenesis imperfecta, alvelestat for alpha-1 antitrypsin deficiency-associated lung disease, and other clinical-stage programs aimed at addressing serious unmet medical needs. Mereo BioPharma Group plc ADR operates as part of the broader biotechnology sector, where it contributes to the advancement of specialized treatments through clinical development and targeted research. The company is headquartered in London and maintains a presence in both the United Kingdom and the United States, serving patients and medical communities through its pipeline of investigational therapies.

Website

Location

One Cavendish Place

London, W1G 0QF

United Kingdom

Social

What share of all stock conversation is about MREO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0% +0	0% 0	0% +0

Sep 23

Mereo BioPharma Group plc's stock price has broken new highs, reaching over $0.04.
Some investors are holding onto their shares, despite the stock's volatility, and are optimistic about its potential.
There is speculation that Syntln will confirm the execution of Avlestat's options, which could have a significant impact on Mereo BioPharma Group plc's future.

Generated by AI

Sentiment

Of the messages about MREO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	94.57% -0.83	90.42% +8.55	82.68% +4.1
Bearish	0% 0	5.43% +0.83	9.58% -8.55	17.32% -4.1

Bullish· Aug 11

The company's market capitalization is around $50M, and with the pro-form cash, the valuation seems reasonable, especially considering the deal is not yet closed.
The recent news has surprised some investors, and with the potential for another extension, it could be interesting to see if the stock makes an organic move up.
The chart is very bullish, and with a large volume of 32 mil premarket, the stock could test $1, and there's still room on the chart for a move overhead.

Bearish· Jan 20

The author suggests that the recent surge in MREO's price is due to manipulation rather than genuine momentum.
The stock's structure is broken, and it has shifted to a clear downtrend with lower highs and bearish momentum.
The author believes that MREO's price drop is due to a lack of fundamental value and is being driven by a scam or a fake biopharm stock.

Generated by AI

Topics

Of the messages about MREO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	90.63%	95.08%	66.14%
Technical Analysis	50%	6.25%	3.28%	5.1%
Earnings	0%	0%	0%	1.64%
Analysts	50%	3.13%	1.64%	13.28%
Controversies	0%	0%	0%	2.29%
Macro	0%	0%	0%	11.55%

Announcements· Aug 11

Mereo BioPharma Group plc has entered into an option and license agreement with Sentynl Therapeutics for the US rights to alvelestat, a potential first-in-class oral treatment for alpha-1 antitrypsin deficiency-associated lung disease, with Mereo eligible to receive $40M in upfront payments and up to $435M in milestones.
The agreement also includes double-digit tiered royalties on U.S. net sales of alvelestat, and Sentynl gains US commercial rights and worldwide manufacturing of alvelestat for AATD-associated lung disease.
Mereo BioPharma has announced its second-quarter 2026 results, with a narrowed net loss of $7.0 million, and has extended its cash runway into late 2027 as the Phase 3 partnership advances for alvelestat in AATD-LD.

Technical Analysis· Jun 17

$MREO will steady climb all day, with pull backs after new highs bringing intraday RSI back to oversold quickly.
A trend line for $MREO is expected to hold, with bulls in control as long as it does, and a potential breakout to 1.60-1.70 if it retests highs.
$MREO has positive volume and a head and shoulders pattern, with a potential next leg taking it to 1.60-1.70, and a re-test of 1.58 before breaking through.

Generated by AI

Community

Of the messages about MREO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	53.66%	57.14%	59.18%	44.09%
Newcomers	46.34%	42.86%	40.82%	55.91%

Regulars· Aug 11

Mereo BioPharma and Sentynl Therapeutics have entered into an option and license agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease, with Mereo eligible to receive $40M in upfront payments and up to $435M in milestones.
The agreement is expected to advance the Phase 3 study design for alvelestat, with the companies collaborating to refine the global study design and advance manufacturing.
Mereo's stock price has surged following the announcement, with some analysts predicting the company may be acquired by Zydus Lifesciences Ltd, and others anticipating potential milestone payments of up to $669M.

Newcomers· Sep 23

The newcomers are focused on the potential for a significant increase in the price of Mereo BioPharma Group plc, with some users expressing excitement about the possibility of the stock "popping" overnight.
The users are discussing various price levels and targets, including adding shares when the price reaches $1.75 and selling for $2 or more.
There is speculation about upcoming catalysts and the possibility of investors averaging up, with one user suggesting that the stock may be moving due to news from Syntln about the execution of Avlestat's options.

Generated by AI

Mereo BioPharma Group

Social

Sep 23

Bullish· Aug 11

Bearish· Jan 20

Announcements· Aug 11

Technical Analysis· Jun 17

Regulars· Aug 11

Newcomers· Sep 23

Cantor Fitzgerald reiterates Mereo BioPharma stock Overweight rating at $3

Analysts Conflicted on These Healthcare Names: Veeva Systems (VEEV), Mereo Biopharma Group Plc (MREO) and Tvardi Therapeutics (TVRD)

Mereo BioPharma receives extension from Nasdaq to regain minimum bid price compliance

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances

Mereo BioPharma licenses alvelestat to Sentynl Therapeutics

Also Discussed

Mereo BioPharma Group plc ADR

Company Information

Location

Cantor Fitzgerald reiterates Mereo BioPharma stock Overweight rating at $3

Analysts Conflicted on These Healthcare Names: Veeva Systems (VEEV), Mereo Biopharma Group Plc (MREO) and Tvardi Therapeutics (TVRD)

Mereo BioPharma receives extension from Nasdaq to regain minimum bid price compliance

Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat

Mereo BioPharma Extends Cash Runway Into Late 2027 as Alvelestat Phase 3 Partnership Advances

Mereo BioPharma licenses alvelestat to Sentynl Therapeutics

Also Discussed

Social

Sep 23

Bullish· Aug 11

Bearish· Jan 20

Announcements· Aug 11

Technical Analysis· Jun 17

Regulars· Aug 11

Newcomers· Sep 23